ERBB2-Targeting Antibody Epitope Binding for Low Expression Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody therapies for cancer, such as Trastuzumab and Pertuzumab, are effective only for patients with ERBB2-overexpressing or amplified breast cancer, leaving approximately 70% of patients with ERBB2-low tumors without treatment options and facing resistance to treatment, necessitating the development of additional antibodies that can target ERBB2 in both high and low expression settings.
Innovation Solution
A novel antibody, mAb W6/800, is identified and characterized to bind a unique epitope on the ERBB2 receptor, demonstrating synergistic interference with receptor-mediated signaling and tumor regression in both ERBB2-high and ERBB2-low tumors, capable of combining with Trastuzumab and Pertuzumab for enhanced therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Trastuzumab and Pertuzumab are used to target ERBB2, then therapeutic effect is achieved in ERBB2-overexpressing patients, but treatment coverage is limited to only 30% of breast cancer patients
Solution Approach 1:
The patent develops a novel antibody (mAb W6/800) that targets ERBB2 with a different epitope than Trastuzumab and Pertuzumab, enabling it to function effectively across both ERBB2-high and ERBB2-low tumor types. This universal approach allows a single antibody to address multiple patient populations that previously required different treatment strategies or no treatment at all.
2Adaptability or versatility
If additional antibodies are developed to expand treatment coverage, then applicative range is extended to ERBB2-low patients, but device complexity increases
Solution Approach 1:
The patent segments the ERBB2 target into multiple distinct epitopes, each recognized by different antibodies (Trastuzumab, Pertuzumab, and mAb W6/800). This segmentation allows each antibody to target specific regions of the ERBB2 receptor, enabling combination therapies that can overcome resistance mechanisms and expand coverage to ERBB2-low patients without requiring a single complex multi-functional antibody.
3Reliability
If novel antibodies are designed to target unique epitopes, then synergistic effects are achieved with existing therapies, but manufacturing precision requirements increase
Solution Approach 1:
The patent introduces mAb W6/800 as an intermediary antibody that bridges the gap between existing Trastuzumab/Pertuzumab therapies and ERBB2-low tumors. By targeting a unique epitope that does not overlap with other antibodies, it mediates synergistic effects when combined with existing therapies, while its distinct binding site simplifies manufacturing by avoiding cross-reactivity and complex purification requirements.
Data Source
AI summary
The present invention relates to an antibody, particularly a monoclonal antibody, which binds a novel epitope of the ERBB2 tyrosine kinase receptor, wherein the unique features of said binding enable interference with receptor-mediated signalling and downstream biological effects in a novel and unanticipated fashion not obtainable with state-of-the-art therapeutic antibodies. The present invention relates to compositions comprising such an antibody and its humanized derivative, as well as methods using such an antibody and derivative, particularly in ERBB2-low/non-amplified breast cancers, particularly in combination with Trastuzumab and Pertuzumab.